GSK3532795  (Synonyms: BMS-955176)

GSK3532795 (BMS-955176) is a potent, orally active, second-generation HIV-1 maturation inhibitor, with EC₅₀s of 1.9, 10.2, 2.7 and 13 nM for HIV-1 WT, HIV-1 WT(human serum), HIV-1 V370A, and HIV-1 ΔV370, respectively^[1].

EC50: 1.9 nM (HIV-1 WT), 10.2 nM (HIV-1 WT(human serum)), 2.7 nM (HIV-1 V370A), 13 nM (HIV-1 ΔV370)^[1]

GSK3532795 exhibits K_ds of 3.2 ± 0.6, 4.3 ± 2.0, 6.5 ± 2.2 and 33.6 ± 5.9 nM for HIV WT, HIV V362I, HIV V370A, HIV ΔV370, respectively^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

691.02

C₄₂H₆₂N₂O₄S

1392312-45-6

固体

White to off-white

Room temperature in continental US; may vary elsewhere.

• [1]. Regueiro-Ren A, et al. Design, Synthesis, and SAR of C-3 Benzoic Acid, C-17 Triterpenoid Derivatives. Identification of the HIV-1 Maturation Inhibitor 4-((1 R,3a S,5a R,5b R,7a R,11a S,11b R,13a R,13b R)-3a-((2-(1,1-Dioxidothiomorpholino)ethyl)amino)-5a,5  [Content Brief]